Tower Research Capital LLC (Trc) Greenwich Life Sciences, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.31 - $20.32 $7,528 - $18,409	-906 Reduced 63.09%	530 $10,000
Q4 2023 Feb 13, 2024	BUY	$7.77 - $12.3 $1,087 - $1,722	140 Added 10.8%	1,436 $15,000
Q3 2023 Nov 14, 2023	BUY	$8.41 - $10.66 $571 - $724	68 Added 5.54%	1,296 $11,000
Q2 2023 Aug 14, 2023	BUY	$9.58 - $13.2 $1,216 - $1,676	127 Added 11.53%	1,228 $11,000
Q1 2023 May 09, 2023	BUY	$12.12 - $20.8 $12,713 - $21,819	1,049 Added 2017.31%	1,101 $15,000
Q4 2022 Feb 10, 2023	BUY	$9.04 - $16.88 $470 - $877	52 New	52 $1,000
Q2 2022 Aug 15, 2022	BUY	$7.14 - $20.36 $5,683 - $16,206	796 Added 160.81%	1,291 $11,000
Q1 2022 May 12, 2022	SELL	$16.3 - $24.65 $6,536 - $9,884	-401 Reduced 44.75%	495 $10,000
Q4 2021 Feb 14, 2022	BUY	$21.76 - $39.43 $14,122 - $25,590	649 Added 262.75%	896 $22,000
Q3 2021 Nov 15, 2021	SELL	$38.65 - $46.11 $1,584 - $1,890	-41 Reduced 14.24%	247 $10,000
Q2 2021 Aug 16, 2021	SELL	$31.24 - $53.6 $48,890 - $83,884	-1,565 Reduced 84.46%	288 $13,000
Q1 2021 May 17, 2021	BUY	$22.37 - $39.98 $41,451 - $74,082	1,853 New	1,853 $63,000

1.01M

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $173M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.